ArticleJournal of the National Cancer Institute2026
Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
backgroundRestaging after neoadjuvant chemotherapy aims to assess treatment response, revise prognosis, and guide further management. This study investigated independent prognostic factors for overall survival after restaging in patients with localized pancreatic adenocarcinoma.
methodsIn this retrospective international study, consecutive patients with localized pancreatic adenocarcinoma who received at least 1 cycle of (m)FOLFIRINOX as first-line therapy were identified. Multivariable Cox regression analysis was performed with a web-based calculator to predict individualized overall survival.
resultsThe Trans-Atlantic Pancreatic Surgery cohort included 2338 patients with localized pancreatic adenocarcinoma of whom 22.6% were potentially resectable, 30.7% borderline resectable, and 46.7% locally advanced at initial staging. Several baseline characteristics remained independent prognostic factors for overall survival after restaging: borderline resectable (hazard ratio [HR] = 1.31, 95% confidence interval [CI] = 1.14 to 1.51), locally advanced (HR = 1.78, 95% CI = 1.55 to 2.05), body or tail tumor (HR = 0.79, 95% CI = 0.68 to 0.90), and baseline World Health Organization performance status of 1 (HR = 1.18, 95% CI = 1.07 to 1.30) or at least 2 (HR = 1.54, 95% CI = 1.20 to 1.98). Additional independent factors were metastatic disease at restaging (HR = 1.57, 95% CI = 1.31 to 1.87), postinduction carbohydrate antigen 19-9 (HR = 1.47, 95% CI = 1.37 to 1.57), Δcarbohydrate antigen 19-9 (HR = 0.83, 95% CI = 0.77 to 0.89), postinduction tumor size (HR = 1.22, 95% CI = 1.11 to 1.35), and Δtumor size (HR = 0.92, 95% CI = 0.87 to 0.98). Patients were stratified into 4 risk groups, with 3-year overall survival after restaging ranging from 6.0% to 65.8%.
conclusionSurvival at restaging after neoadjuvant chemotherapy of patients with localized pancreatic adenocarcinoma is determined by 8 patient, tumor, and treatment response characteristics. A web-based calculator can inform clinicians and patients about individualized prognosis and guide further management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.